# Chronic Obstructive Pulmonary Disease Endpoints Study

> **NCT00358358** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 163 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Fluticasone Propionate/Salmeterol 500/50mcg combination
- **DRUG:** Fluticasone Propionate 500mcg
- **DRUG:** Salmeterol 50mcg

## Key facts

- **NCT ID:** NCT00358358
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2007-02
- **Final completion:** 2007-02
- **Target enrollment:** 163 (ACTUAL)
- **Last updated:** 2017-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00358358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00358358, "Chronic Obstructive Pulmonary Disease Endpoints Study". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00358358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*